RL
72
3
ORCL
58
4
TRV
48
2
NKE
30
2
LB
45
15
O
33
-4
DOV
61
4
KMB
34
6
D
41
4
FIS
46
-9
CAT
59
4
MLM
58
-2
BMY
43
2
OKE
68
4
DGX
36
3
WU
36
2
JPM
59
3
EFX
40
4
BRK.B
27
2
EXPD
40
3
RL
72
3
ORCL
58
4
TRV
48
2
NKE
30
2
LB
45
15
O
33
-4
DOV
61
4
KMB
34
6
D
41
4
FIS
46
-9
CAT
59
4
MLM
58
-2
BMY
43
2
OKE
68
4
DGX
36
3
WU
36
2
JPM
59
3
EFX
40
4
BRK.B
27
2
EXPD
40
3
Financhill
Back

Apellis Pharmaceuticals 10K Form

Sell
42

APLS
Apellis Pharmaceuticals

Last Price:
29.07
Seasonality Move:
22.1%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive APLS News And Ratings

See the #1 stock for the next 7 days that we like better than APLS

APLS Financial Statistics

Sales & Book Value

Annual Sales: $396.59M
Cash Flow: $-8.43M
Price / Cash Flow: 0
Annual Sales: $2.17
Price / Book: 12.93

Profitability

EPS (TTM): -2.74000
Net Income (TTM): $-332.89M
Gross Margin: $338.08M
Return on Equity: -127.72%
Return on Assets: -39.08%

Apellis Pharmaceuticals Earnings Forecast

Key Apellis Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 6 years for APLS is 85.25%.
  • The Selling, General & Administrative Expenses for APLS have been equal to 126.28% of Gross Profit Margin.
  • The Research & Development expenses have been 89.36% of Revenue.
  • The Interest Expense is -5.60% of Operating Income.
  • The Net Earning history of APLS is -133.29% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Apellis Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: APLS
CUSIP: 03753U
Website: apellis.com

Debt

Debt-to-Equity Ratio: 1.73
Current Ratio: 5.08
Quick Ratio: 3.95

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 160.23

APLS Technical Analysis vs Fundamental Analysis

Sell
42
Apellis Pharmaceuticals (APLS) is a Sell

Is Apellis Pharmaceuticals a Buy or a Sell?